Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Antonio PérezWilliam Valentine

Abstract

Metformin is the first-line therapy for most patients with type 2 diabetes, but the majority require treatment intensification at some stage due to the progressive nature of the disease. The 1860-LIRA-DPP-4 trial showed that liraglutide exhibited greater improvements compared with sitagliptin in glycated hemoglobin and body mass index in patients with type 2 diabetes inadequately controlled on metformin monotherapy. As a follow-up to a previously published cost-effectiveness analysis of 1.2 mg liraglutide versus sitagliptin in Spain, the aim of this analysis was to compare long-term projections of the clinical and cost implications associated with 1.8 mg liraglutide and sitagliptin. For the modeling analysis, 52-week treatment effect data (as opposed to 26-week data in the previous analysis) were taken from the 1860-LIRA-DPP-4 trial, for adults with type 2 diabetes receiving 1.8 mg liraglutide or 100 mg sitagliptin daily in addition to metformin. Long-term (patient lifetime) projections of clinical outcomes and direct costs (2012 EUR) were made using a published and validated model of type 2 diabetes, with modeling assumptions as per the 1.2 mg liraglutide analysis. Liraglutide was associated with increased life expectancy (14....Continue Reading

References

Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
May 6, 2004·The Journal of Clinical Endocrinology and Metabolism·Bo AhrénAnja Schweizer
Aug 25, 2004·Current Medical Research and Opinion·Andrew J PalmerGiatgen A Spinas
Aug 31, 2004·Diabetes Care·UNKNOWN American Diabetes Association Consensus Panel
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Oct 14, 2006·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·M A NauckUNKNOWN NN2211-1499 Study Group
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Apr 21, 2010·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Julio López-BastidaJaume Puig-Junoy
Sep 3, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·M J DaviesW J Valentine
Sep 20, 2011·International Journal of Circumpolar Health·Daria O'ReillyRon Goeree
Apr 17, 2013·International Journal of Technology Assessment in Health Care·Don HusereauUNKNOWN CHEERS Task Force
May 22, 2013·Diabetes Care·David M NathanUNKNOWN GRADE Study Research Group
Aug 31, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Luis-Emilio García-PérezDomingo Orozco-Beltrán
Oct 18, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Pedro Mezquita RayaWilliam J Valentine
Jul 6, 2014·Heart·Dawn LeeUNKNOWN Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Study
Sep 23, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Phil McEwanDavid Grant

❮ Previous
Next ❯

Citations

Oct 19, 2016·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Alexandre BaptistaJulian Perelman
Feb 23, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Pedro Mezquita-RayaBarnaby Hunt
Oct 8, 2020·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·J PöhlmannH Sapin
Dec 3, 2021·Cell Biochemistry and Function·Salma M ErakyNada F Abo El-Magd

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00700817
NCT01794143

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.